TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Proton Pump Inhibitors on CF Exacerbations
Brief Summary: Gastroesophageal reflux disease (GERD) is a common problem in cystic fibrosis (CF). It may lead to worsening lung function and more respiratory infections for a person with CF. This study will look at treating GERD with a medication, esomeprazole. The medication stops stomach acid from being made. The study will see if there are fewer respiratory infections and improved lung function in patients with CF when taking esomeprazole.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
B: Arm Label: Antioxidant-enriched multivitamin supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AquADEK | Intervention Type: DIETARY_SUPPLEMENT; Name: AquADEK; Assigned to Arm(s): Antioxidant-enriched multivitamin supplement
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Esomeprazole | Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): Esomeprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of Volatile Anesthetics for Long-Term Sedation In Critically Ill Patients
Brief Summary: Heavy sedation or sleep is a common problem within the intensive care unit (ICU) using our standard intravenous medications. This commonly leads to confusion, low blood pressure, slow wake up and removal of the artificial breathing tube (extubation), which prolongs ICU stay. Using inhaled volatile anesthetic agents are likely to improve these patient outcomes. This unique project is the first North American study looking at using volatiles for patients who need longer-term ICU sedation. This project has excellent potential at lowering these complications and improving quality of care, which will lower patient ICU stay and healthcare costs.


Options:
A: Arm Label: PS; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized Sedation | Arm Label: PS + DI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Protocolized sedation, with daily interruption | Intervention Type: PROCEDURE; Name: Protocolized Sedation; Assigned to Arm(s): PS | Intervention Type: PROCEDURE; Name: Protocolized sedation, with daily interruption; Assigned to Arm(s): PS + DI
B: Arm Label: intravenous propofol/midazolam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Propofol/midazolam | Arm Label: isoflurane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoflurane | Intervention Type: DRUG; Name: Isoflurane; Assigned to Arm(s): isoflurane | Intervention Type: DRUG; Name: Propofol/midazolam; Assigned to Arm(s): intravenous propofol/midazolam
C: Intervention Type: DRUG; Name: Arsenic trioxide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Trisenox; Assigned to Arm(s): N/A
D: Arm Label: Early PT OT; Type: EXPERIMENTAL; Interventions: Procedure: early PT OT | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: early PT OT; Assigned to Arm(s): Early PT OT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care
Brief Summary: The trial will examine whether a centralized Prevention Health \& Cardiovascular Risk Service (PHCVRS) run by clinical pharmacists at the University of Iowa can be implemented in primary care offices and whether it can improve the care delivered to patients at risk for developing cardiovascular disease.


Options:
A: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Intervention Type: BEHAVIORAL; Name: Education for diabetes self-management; Assigned to Arm(s): N/A
C: Arm Label: PHCVRS intervention; Type: EXPERIMENTAL; Interventions: Other: PHCVRS Intervention, Other: Personal Health Record | Arm Label: Usual care/Personal Health Record; Type: OTHER; Interventions: Other: Personal Health Record | Intervention Type: OTHER; Name: PHCVRS Intervention; Assigned to Arm(s): PHCVRS intervention | Intervention Type: OTHER; Name: Personal Health Record; Assigned to Arm(s): PHCVRS intervention, Usual care/Personal Health Record
D: Arm Label: SMS texting intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS texting intervention | Arm Label: Control-Usual Care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Control-Usual Care | Intervention Type: BEHAVIORAL; Name: SMS texting intervention; Assigned to Arm(s): SMS texting intervention | Intervention Type: BEHAVIORAL; Name: Control-Usual Care; Assigned to Arm(s): Control-Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care
Brief Summary: The trial will examine whether a centralized Prevention Health \& Cardiovascular Risk Service (PHCVRS) run by clinical pharmacists at the University of Iowa can be implemented in primary care offices and whether it can improve the care delivered to patients at risk for developing cardiovascular disease.


Options:
A: Arm Label: Advice on DDIs; Type: EXPERIMENTAL; Interventions: Behavioral: Advice on DDIs | Arm Label: General advice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Advice on DDIs; Assigned to Arm(s): Advice on DDIs
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemonitors and pharmacy management; Type: EXPERIMENTAL; Interventions: Other: Telemonitors and pharmacy management | Intervention Type: OTHER; Name: Telemonitors and pharmacy management; Assigned to Arm(s): Telemonitors and pharmacy management
C: Arm Label: PHCVRS intervention; Type: EXPERIMENTAL; Interventions: Other: PHCVRS Intervention, Other: Personal Health Record | Arm Label: Usual care/Personal Health Record; Type: OTHER; Interventions: Other: Personal Health Record | Intervention Type: OTHER; Name: PHCVRS Intervention; Assigned to Arm(s): PHCVRS intervention | Intervention Type: OTHER; Name: Personal Health Record; Assigned to Arm(s): PHCVRS intervention, Usual care/Personal Health Record
D: Arm Label: Intensive pharmacist case management; Type: EXPERIMENTAL; Interventions: Drug: Antihypertensive agents and lipid lowering therapy | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DRUG; Name: Antihypertensive agents and lipid lowering therapy; Assigned to Arm(s): Intensive pharmacist case management | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Brief Summary: This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed, inoperable, locally advanced or metastatic renal cell carcinoma who have not received prior systemic therapy either in the adjuvant or metastatic setting.


Options:
A: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Drug: Bevacizumab | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon alpha-2a | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Interferon alpha-2a; Assigned to Arm(s): C
C: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: Sorafenib-sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib-sunitinib | Arm Label: Sunitinib-sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib-sorafenib | Intervention Type: DRUG; Name: Sorafenib-sunitinib; Assigned to Arm(s): Sorafenib-sunitinib | Intervention Type: DRUG; Name: Sunitinib-sorafenib; Assigned to Arm(s): Sunitinib-sorafenib

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
Brief Summary: This multicenter, randomized, open-label study will evaluate the efficacy, safety and tolerability of atezolizumab as monotherapy or in combination with bevacizumab versus sunitinib in participants with histologically confirmed, inoperable, locally advanced or metastatic renal cell carcinoma who have not received prior systemic therapy either in the adjuvant or metastatic setting.


Options:
A: Arm Label: Atezolizumab and Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Drug: Bevacizumab, Drug: Sunitinib | Intervention Type: DRUG; Name: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Atezolizumab, Atezolizumab and Bevacizumab, Sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
B: Arm Label: everolimus 1L/sunitinib 2L; Type: EXPERIMENTAL; Interventions: Drug: everolimus, Drug: sunitinib | Arm Label: sunitinib 1L/everolimus 2L; Type: ACTIVE_COMPARATOR; Interventions: Drug: everolimus, Drug: sunitinib | Intervention Type: DRUG; Name: everolimus; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): everolimus 1L/sunitinib 2L, sunitinib 1L/everolimus 2L
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: temsirolimus (Torisel) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: temsirolimus (Torisel); Assigned to Arm(s): 2
D: Arm Label: Sunitinib 4/2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib 4/2 | Arm Label: Sunitinib 2/1; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 2/1; Assigned to Arm(s): Sunitinib 2/1 | Intervention Type: DRUG; Name: Sunitinib 4/2; Assigned to Arm(s): Sunitinib 4/2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combining Cabergoline and Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS): a Randomized Clinical Trial
Brief Summary: The effectiveness of cabergoline to prevent moderate-severe OHSS to coasting.


Options:
A: Arm Label: Coasting; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Arm Label: Cabergoline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Arm Label: Coasting and Cabergoline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ICSI | Intervention Type: PROCEDURE; Name: ICSI; Assigned to Arm(s): Cabergoline, Coasting, Coasting and Cabergoline
B: Arm Label: Cabergoline group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cabergoline | Arm Label: GnRH antagonist rescue & cabergoline group; Type: EXPERIMENTAL; Interventions: Drug: GnRH antagonist rescue & cabergoline | Intervention Type: DRUG; Name: Cabergoline; Assigned to Arm(s): Cabergoline group | Intervention Type: DRUG; Name: GnRH antagonist rescue & cabergoline; Assigned to Arm(s): GnRH antagonist rescue & cabergoline group
C: Arm Label: Hemoes; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cabergoline; Type: EXPERIMENTAL; Interventions: Drug: Cabergoline and Hydroxyethyl Starch, Drug: Hydroxyethyl Starch | Intervention Type: DRUG; Name: Cabergoline and Hydroxyethyl Starch; Assigned to Arm(s): Cabergoline | Intervention Type: DRUG; Name: Hydroxyethyl Starch; Assigned to Arm(s): Cabergoline
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Norprolac | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Norprolac | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Norprolac; Assigned to Arm(s): 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a Double-Blind Placebo-Controlled 2-Period Crossover Study to Evaluate the Safety and Efficacy of BCX4161 as a Prophylactic Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema
Brief Summary: The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic treatment is safe and effective in reducing the number of acute attacks in patients with hereditary angioedema.


Options:
A: Arm Label: BCX4161; Type: ACTIVE_COMPARATOR; Interventions: Drug: BCX4161 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: C1INH-nf; Type: EXPERIMENTAL; Interventions: Biological: C1 esterase inhibitor [human] (C1INH-nf) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (saline) | Intervention Type: BIOLOGICAL; Name: C1 esterase inhibitor [human] (C1INH-nf); Assigned to Arm(s): C1INH-nf | Intervention Type: DRUG; Name: Placebo (saline); Assigned to Arm(s): Placebo
C: Arm Label: C1-INH - low-volume dose; Type: EXPERIMENTAL; Interventions: Biological: C1-esterase inhibitor | Arm Label: C1-INH - medium-volume dose; Type: EXPERIMENTAL; Interventions: Biological: C1-esterase inhibitor | Intervention Type: BIOLOGICAL; Name: C1-esterase inhibitor; Assigned to Arm(s): C1-INH - low-volume dose, C1-INH - medium-volume dose
D: Arm Label: BCX4161 300 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161, Drug: Placebo | Arm Label: BCX4161 500 mg three times daily; Type: EXPERIMENTAL; Interventions: Drug: BCX4161 | Arm Label: Placebo three times daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BCX4161; Assigned to Arm(s): BCX4161 300 mg three times daily, BCX4161 500 mg three times daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BCX4161 300 mg three times daily, Placebo three times daily

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of Telemedicine for Chronic Obstructive Pulmonary Disease: The Danish "TeleCare North" Pragmatic Cluster-randomized Trial.
Brief Summary: There are two main aims in this study. The first objective is to evaluate whether a particular telehealth solution, in addition to standard treatment and care, lead to a significant decrease in the mortality and an increase in health related quality of life for patients suffering from COPD that may benefit from telehealth compared with only standard treatment and care. The second objective is to examine the additional costs of the telehealth solution and assess whether this solution is a cost-effective way to care for patients with COPD across patients and municipality districts.

It is hypothesized that telehealth care will increase patients quality adjusted life years at both the cluster and individual level compared to usual practice, since no difference in mortality and a higher health related quality of life is expected. Furthermore, it is hoped that there will be a 30% reduction in the number of admissions and readmissions to hospitals and a 30% reduction in the number of outpatient visits resulting in fewer costs for hospitals. However, it is uncertain as to whether these savings are offset by other costs such as more visits to general practitioners, community care or the implementation costs.


Options:
A: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Mobile App device; Type: EXPERIMENTAL; Interventions: Device: COPDPredict mobile App | Intervention Type: DEVICE; Name: COPDPredict mobile App; Assigned to Arm(s): Mobile App device | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Opinion leader educational letter | Arm Label: Control/Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Opinion leader educational letter; Assigned to Arm(s): Intervention Arm
C: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
D: Arm Label: Education, tele-consultation and training booklet; Type: EXPERIMENTAL; Interventions: Behavioral: education and tele-consultation | Arm Label: Standart care, no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: education and tele-consultation; Assigned to Arm(s): Education, tele-consultation and training booklet

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness and Cost-effectiveness of Telemedicine for Chronic Obstructive Pulmonary Disease: The Danish "TeleCare North" Pragmatic Cluster-randomized Trial.
Brief Summary: There are two main aims in this study. The first objective is to evaluate whether a particular telehealth solution, in addition to standard treatment and care, lead to a significant decrease in the mortality and an increase in health related quality of life for patients suffering from COPD that may benefit from telehealth compared with only standard treatment and care. The second objective is to examine the additional costs of the telehealth solution and assess whether this solution is a cost-effective way to care for patients with COPD across patients and municipality districts.

It is hypothesized that telehealth care will increase patients quality adjusted life years at both the cluster and individual level compared to usual practice, since no difference in mortality and a higher health related quality of life is expected. Furthermore, it is hoped that there will be a 30% reduction in the number of admissions and readmissions to hospitals and a 30% reduction in the number of outpatient visits resulting in fewer costs for hospitals. However, it is uncertain as to whether these savings are offset by other costs such as more visits to general practitioners, community care or the implementation costs.


Options:
A: Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Bundle; Type: EXPERIMENTAL; Interventions: Behavioral: Bundle tool | Intervention Type: BEHAVIORAL; Name: Bundle tool; Assigned to Arm(s): Bundle
C: Arm Label: 1: i-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Internet DSMP | Arm Label: 2: f-DSMP; Type: EXPERIMENTAL; Interventions: Behavioral: Face-to-Face Dyspnea Self-management | Arm Label: 3: AC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Attention Control | Intervention Type: BEHAVIORAL; Name: Internet DSMP; Assigned to Arm(s): 1: i-DSMP | Intervention Type: BEHAVIORAL; Name: Face-to-Face Dyspnea Self-management; Assigned to Arm(s): 2: f-DSMP | Intervention Type: BEHAVIORAL; Name: Attention Control; Assigned to Arm(s): 3: AC
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Coaching program; Type: EXPERIMENTAL; Interventions: Other: Coaching program | Intervention Type: OTHER; Name: Coaching program; Assigned to Arm(s): Coaching program

Answer: A